BioNTech buys Biotheus and its Keytruda rival for $950m
BioNTech said that BNT327 has the "potential to replace current checkpoint inhibitor standard of care treatments for solid tumours." It is paying $800 million to acquire all of Biotheus' issued share capital and up to $150 million in potential milestone payments.
BioNTech to buy Biotheus, gaining control of cancer bispecific
Biotheus’ antibody drug targets PD-L1 and VEGF, a design that’s high on drugmakers’ radars after the success of Summit Therapeutics’ ivonescimab.
BioNTech acquires its Chinese cancer drug partner
BioNTech said that it is acquiring the Chinese drugmaker Biotheus for $800 million to bolster its cancer strategy. The two companies were already co-developing an experimental antibody that targets two proteins found on cancer cells.
BioNTech Acquires Biotheus to Enhance Cancer Therapies
BioNTech SE (BNTX) has released an update. BioNTech SE is set to acquire Biotheus in a deal valued at $800 million, aiming to strengthen its
BioNTech strikes $950mn deal for Chinese drugmaker Biotheus
BioNTech has acquired Chinese cancer drugmaker Biotheus in a near $1bn deal, as the Covid-19 vaccine maker taps into the country’s health sciences expertise to develop promising immunotherapy drugs. The deal gives the German biotech control of a drug class that has shown potential to outperform Merck’s blockbuster cancer treatment Keytruda,
BioNTech buys China's Biotheus to support oncology strategy
German drugmaker BioNTech has agreed to acquire Chinese biotech company Biotheus to support its oncology strategy and gain full global rights to the bispecific antibody candidate BNT327, it said on Wednesday.
Germany's BioNTech to buy Chinese firm with promising cancer drug
Germany pharmaceutical company BioNTech, which shot to global prominence after its early coronavirus vaccine, has boosted its cancer drug development by agreeing to buy Chinese firm Biotheus. The Mainz-based group said in a statement on Wednesday it will pay up to $950 million,
The Pharma Letter2d
Merck's Keytruda and Citius' Lymphir combo trial shows promising results
Results from the study, which focused on gynecological malignant tumors, were presented at the Society for Immunotherapy of ...
FierceBiotech1d
Caris scores FDA approval for multi-cancer companion diagnostic test
The FDA’s premarket approval green light spans one pan-cancer ... Finally, the assay can be used with Merck’s Keytruda ...
BioSpace10dOpinion
Opinion: Ten Years After Keytruda’s Seminal Approval, Immuno-oncology Is Poised for the Next Revolution
While some of the initial excitement around immunotherapies has waned, companies—particularly smaller biotechs—are developing ...
MM&M13h
BioNTech spends $800M upfront to pick up China-based Biotheus
Analysts say the drug could emerge as a potential competitor to Merck’s blockbuster immunotherapy Keytruda. Keytruda is ...
Healthline9d
All About Keytruda
Keytruda (pembrolizumab) is a prescription drug that’s used to treat certain forms of cancer. Keytruda comes as an intravenous (IV) infusion (an injection into your vein given over time).
FierceBiotech1d
BioNTech pays $800M to take control of potential Keytruda killer
If, as ivonescimab’s victory over Keytruda suggested, PD-(L ... BioNTech is also exploring combinations with ...
Merck: An Undervalued Dividend Machine
Merck's consistent dividend payments over 34 years, healthy balance sheet, and attractive valuation highlight its investment ...
Pharmaceutical Technology8d
Top 20 biopharmas’ market cap rises 2% in Q3 2024 amid flurry of drug approvals
The top 20 biopharmaceutical companies demonstrated signs of recovery during the third quarter (Q3) of 2024 as investor ...
The Daily Telegraph10d
‘Life changing’ multi-cancer drug funding proposal in jeopardy
Natalie Willacy has so far poured $40,000 of her super into self-funding her own immunotherapy treatment with the ...